Medical device and IoMT security
Medical device security assessment for clearer connected-care risk priorities
Understand where connected medical devices create security exposure across your care environment. A scoped review examines visibility, access and vendor dependencies to inform architecture recommendations and a prioritized remediation roadmap.
MIS
CISSP
CHISL
CPHIMS
CDH-E
Will Long Sr. · Founder
MIS · CHISL · CDH-E · CISSP · CPHIMS
Nearly 40 years in IT & cybersecurity
Former VP & CISO, Children’s Health System of Texas
Tim Pelikan · Co-Founder
Credential details pending confirmation
30 years in cybersecurity & data risk
Interviews & industry conversations
Coffee With Closers
Cybersecurity With Discern
“ICA provides distinctive security professionals who excel at building strong client relationships, demonstrate exceptional organization, and deliver practical, risk-based consulting recommendations to our clients.”
Michael Cox, CIPP/US
Chief Privacy Consultant & Founder, SoCal Privacy Consultants
Partner endorsement of ICA’s advisory work
Make connected-care risk a shared decision
Your connected-device fleet has grown, but clinical engineering and hospital IT may hold different records of what is connected. A new deployment or disruption concern can expose uncertainty about device-security ownership.
This assessment is intended for clinical engineering, CISOs and patient-care operations working with hospital IT. It helps these teams decide which visibility gaps, access arrangements and architecture concerns deserve attention first. Connected medical-device security issues can affect care delivery. Priorities therefore need clinical context alongside technical evidence.
Review the devices and dependencies within scope
The Internet of Medical Things, or IoMT, includes connected medical devices in your care environment. Scope is agreed by device type and site, with the relevant vendors and available passive evidence identified before review.
Coverage considers whether existing records give your team a usable view of the selected devices. The review examines access arrangements and how network segmentation separates device communications from other environments. Vendor dependencies and risk-management practices help explain what your organization controls directly and where manufacturer involvement is needed.
A selected fleet or care area can provide a focused starting point. Findings apply only to the agreed boundary.
Use passive evidence and clinical context
The proposed approach is a clinical and technical specialist review centered on existing evidence. Interviews establish how devices support care and how responsibility is shared between clinical engineering, IT and vendors. Relevant materials may include device inventories, network diagrams, access records and manufacturer security information.
Where available and approved for review, existing monitoring records can help explain connections without introducing active probing. Evidence review distinguishes documented arrangements from assumptions. Missing or conflicting records remain visible in the findings.
This approach does not default to vulnerability scanning or penetration testing. Any active testing needs separate agreement on authorized assets and rules of engagement. Patient-connected devices require explicit authorization and a determination that the proposed activity is safe. Intrusive safety-critical changes are outside the default review.
Turn findings into remediation priorities
Typical deliverables are agreed in scope:
Device-risk findings. Document observed exposure and evidence gaps within the selected environment. Clinical engineering and security owners use these findings to discuss device-specific concerns and unresolved vendor questions.
Architecture recommendations. Explain recommended changes to device access or network separation where the review identifies a need. Infrastructure teams can evaluate those recommendations against required clinical communications and manufacturer constraints.
Prioritized remediation roadmap. Sequence recommended risk treatment so leadership can plan work and involve the appropriate delivery owners. The roadmap supports decisions about what to address first and what needs further validation.
A finding does not establish that a proposed change has been implemented or clinically validated.
Prepare clinical engineering and IT for scoping
Begin with the care setting and the decision you need to make. Identify the device types and sites involved, together with the people responsible for clinical use, network access and vendor support.
Cost and timing depend on fleet diversity, site coverage, vendor dependencies and the quality of available evidence. Specialist requirements and access restrictions also shape the engagement. Agree participation and evidence access before work begins. Sensitive technical records need an agreed handling method.
Keep patient-care and approval boundaries clear
This assessment provides security findings and planning recommendations. It is not product certification or clinical safety approval. Manufacturer coordination matters when evaluating device limitations and appropriate protection measures.
Remediation execution, ongoing device monitoring and retesting require separate scope. The passive review also differs from an authorized penetration test that actively investigates exploitable weaknesses. A broader HIPAA risk analysis considers the organization's electronic protected health information beyond the selected devices. Use the device findings as relevant input rather than treating this review as a substitute for that analysis.
Medical device security assessment FAQs
Who should participate in this assessment?
Clinical engineering and hospital IT are central participants. Include the CISO or security owner and representatives who understand patient-care dependencies. Vendor input may be needed where device restrictions or support arrangements limit the evidence your organization holds.
Can we focus on one device fleet or hospital site?
Yes. The intended scope can focus on agreed device types or sites. Define the associated access paths and vendors as part of that boundary. The report should make clear which environments remain outside the review.
Will the assessment actively scan patient-connected devices?
The proposed review centers on passive evidence. Active scanning and penetration testing are separately scoped methods. Activity involving patient-connected devices requires explicit authorization and safety review; it is not included by default.
What determines the engagement's cost and timing?
Device diversity, site count and vendor involvement affect the work. Evidence availability, clinical participation and access restrictions also matter. These details, together with the required specialist scope, establish the basis for an engagement estimate.
How does this differ from a network security assessment?
A network review concentrates on network controls and architecture. This assessment connects access and segmentation observations to the selected medical devices, clinical dependencies and vendor constraints. The appropriate choice depends on the decision your teams need to make.
Does the roadmap include fixing devices or approving their safety?
The roadmap recommends prioritized remediation. Your organization and relevant vendors remain responsible for evaluating and implementing changes through appropriate clinical and technical processes. Implementation is separately agreed. The assessment does not certify a product or provide clinical safety approval.
Define the connected-care exposure you need to understand
Bring clinical engineering and hospital IT around a specific device-security decision. Discuss a scope that turns available evidence into device-risk findings, architecture recommendations and a remediation roadmap your teams can evaluate against care-delivery needs.
Make connected-care risk a shared decision
Your connected-device fleet has grown, but clinical engineering and hospital IT may hold different records of what is connected. A new deployment or disruption concern can expose uncertainty about device-security ownership.
This assessment is intended for clinical engineering, CISOs and patient-care operations working with hospital IT. It helps these teams decide which visibility gaps, access arrangements and architecture concerns deserve attention first. Connected medical-device security issues can affect care delivery. Priorities therefore need clinical context alongside technical evidence.
Review the devices and dependencies within scope
The Internet of Medical Things, or IoMT, includes connected medical devices in your care environment. Scope is agreed by device type and site, with the relevant vendors and available passive evidence identified before review.
Coverage considers whether existing records give your team a usable view of the selected devices. The review examines access arrangements and how network segmentation separates device communications from other environments. Vendor dependencies and risk-management practices help explain what your organization controls directly and where manufacturer involvement is needed.
A selected fleet or care area can provide a focused starting point. Findings apply only to the agreed boundary.
Use passive evidence and clinical context
The proposed approach is a clinical and technical specialist review centered on existing evidence. Interviews establish how devices support care and how responsibility is shared between clinical engineering, IT and vendors. Relevant materials may include device inventories, network diagrams, access records and manufacturer security information.
Where available and approved for review, existing monitoring records can help explain connections without introducing active probing. Evidence review distinguishes documented arrangements from assumptions. Missing or conflicting records remain visible in the findings.
This approach does not default to vulnerability scanning or penetration testing. Any active testing needs separate agreement on authorized assets and rules of engagement. Patient-connected devices require explicit authorization and a determination that the proposed activity is safe. Intrusive safety-critical changes are outside the default review.
Turn findings into remediation priorities
Typical deliverables are agreed in scope:
Device-risk findings. Document observed exposure and evidence gaps within the selected environment. Clinical engineering and security owners use these findings to discuss device-specific concerns and unresolved vendor questions.
Architecture recommendations. Explain recommended changes to device access or network separation where the review identifies a need. Infrastructure teams can evaluate those recommendations against required clinical communications and manufacturer constraints.
Prioritized remediation roadmap. Sequence recommended risk treatment so leadership can plan work and involve the appropriate delivery owners. The roadmap supports decisions about what to address first and what needs further validation.
A finding does not establish that a proposed change has been implemented or clinically validated.
Prepare clinical engineering and IT for scoping
Begin with the care setting and the decision you need to make. Identify the device types and sites involved, together with the people responsible for clinical use, network access and vendor support.
Cost and timing depend on fleet diversity, site coverage, vendor dependencies and the quality of available evidence. Specialist requirements and access restrictions also shape the engagement. Agree participation and evidence access before work begins. Sensitive technical records need an agreed handling method.
Keep patient-care and approval boundaries clear
This assessment provides security findings and planning recommendations. It is not product certification or clinical safety approval. Manufacturer coordination matters when evaluating device limitations and appropriate protection measures.
Remediation execution, ongoing device monitoring and retesting require separate scope. The passive review also differs from an authorized penetration test that actively investigates exploitable weaknesses. A broader HIPAA risk analysis considers the organization's electronic protected health information beyond the selected devices. Use the device findings as relevant input rather than treating this review as a substitute for that analysis.
Medical device security assessment FAQs
Who should participate in this assessment?
Clinical engineering and hospital IT are central participants. Include the CISO or security owner and representatives who understand patient-care dependencies. Vendor input may be needed where device restrictions or support arrangements limit the evidence your organization holds.
Can we focus on one device fleet or hospital site?
Yes. The intended scope can focus on agreed device types or sites. Define the associated access paths and vendors as part of that boundary. The report should make clear which environments remain outside the review.
Will the assessment actively scan patient-connected devices?
The proposed review centers on passive evidence. Active scanning and penetration testing are separately scoped methods. Activity involving patient-connected devices requires explicit authorization and safety review; it is not included by default.
What determines the engagement's cost and timing?
Device diversity, site count and vendor involvement affect the work. Evidence availability, clinical participation and access restrictions also matter. These details, together with the required specialist scope, establish the basis for an engagement estimate.
How does this differ from a network security assessment?
A network review concentrates on network controls and architecture. This assessment connects access and segmentation observations to the selected medical devices, clinical dependencies and vendor constraints. The appropriate choice depends on the decision your teams need to make.
Does the roadmap include fixing devices or approving their safety?
The roadmap recommends prioritized remediation. Your organization and relevant vendors remain responsible for evaluating and implementing changes through appropriate clinical and technical processes. Implementation is separately agreed. The assessment does not certify a product or provide clinical safety approval.
Define the connected-care exposure you need to understand
Bring clinical engineering and hospital IT around a specific device-security decision. Discuss a scope that turns available evidence into device-risk findings, architecture recommendations and a remediation roadmap your teams can evaluate against care-delivery needs.